Nature Cancer

Article	Citations
Outcompeting neighbors for intestinal cancer initiation	633
Gut decisions in CAR T cell therapy	433
Untangling the threads of immunotherapy research	431
Enhancing childhood cancer targetability	428
Shooting for multiplexed pathology with Orion	357
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	349
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	330
Breaking frontiers with multidisciplinary cancer research	328
A low-coverage liquid biopsy for lung cancer	289
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	268
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	260
A macrophage-activated abscopal effect	251
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	226
An oncolytic circular RNA therapy	225
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	215
PARP11 interfer(on)es with CAR T cell efficacy	213
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	202
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	159
Considering molecular alterations as pan-cancer tissue-agnostic targets	159
MALAT1 protects dormant tumor cells from immune elimination	159
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	146
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	146
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	142
The cGAS–STING pathway and cancer	136
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	136

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	132
DePICting T cell–APC crosstalk in cancer	124
Beating cancer one carbon at a time	122
Expanding the options for KRAS inhibition	121
Palmitate oxidation drives a pro-metastatic post-translational modification	119
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	117
The importance of being generous	115
Stress granules shape metabolic reprogramming and drug resistance	115
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	112
Bone marrow progenitor-like cells against leukemia cure	111
Shaping the microenvironment in peritoneal metastases	110
Reflecting on the golden age of cancer research	109
Determinants of resistance and response to melanoma therapy	107
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	100
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	97
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	97
Advancing therapeutics in small-cell lung cancer	95
Impact of context-dependent autophagy states on tumor progression	94
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	94
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	93
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	93
Innate immunity drives epithelial cell plasticity during prostate tumor formation	92
Sarcoma ecotypes determine immunotherapy benefit	91
Thriving in diverse ecosystems	91
Antibody avidity meets multiple myeloma	91
Evolving landscape of nasopharyngeal carcinoma therapy	90
Inflammation meets translation in AML	90
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	89
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	89
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	89
Cycling back to folate metabolism in cancer	88
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	87
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	86
Key insights from ESMO Congress 2025	86
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	85
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	81
A comeback for checkpoint inhibition in multiple myeloma	81
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	77
LAG-3 and PD-1 blockade raises the bar for melanoma	76
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	75
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	74
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	74
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	73
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	73
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	72
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	71
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	71
Radioligand cancer therapy comes to the fore	70
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	69
Radiation sparks a dark side in neutrophils	68

Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	67
Building a translational cancer dependency map for The Cancer Genome Atlas	67
Multimodal data integration improves immunotherapy response prediction	67
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	67
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	66
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	65
Bispecific antibodies seek out colon cancer stem cells	65
Immunotargeting of a recurrent AML-specific neoantigen	65
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	64
Dual inhibition of EGFR and PI3K with a single drug	63
How AI agents will change cancer research and oncology	63
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	63
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	62
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	62
GEMys homing in on metastasis	61
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	61
Selective targeting of malignant T cells	60
Highlights from the 2025 ASCO Annual Meeting	59
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	59
AKTing on XPO1 inhibition in AML	59
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	59
Targeting BRCA-mutated tumors in mitosis	59
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	58
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	57
Bispecific chimeric T cell receptors tackle tumor heterogeneity	57
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	57
Advances in antibody-based therapy in oncology	56
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	56
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	56
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	56
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition	55
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	55
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	55
The tumor microenvironment’s role in the response to immune checkpoint blockade	55
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	55
Anything to declare?	54
Epigenetic plasticity in PDAC	53
Neoadjuvant immunotherapy marks a new era in oncology	53
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	53
An unexpected career in cancer metabolism	52
Myeloma evades T cell-engaging therapies	52
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	52
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	52
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	52
Metabolic symbiosis in pancreatic cancer	52
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	51
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	50
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	50
There are gremlins in prostate cancer	50
Ricolinostat is not a highly selective HDAC6 inhibitor	50
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	49
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	49
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	49
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	49
In vivo macrophage engineering for renal cancer therapy	48
p53 at the crossroads of tumor immunity	48
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	48
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	48
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	47
Clinical and translational attributes of immune-related adverse events	46
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	46
Circumventing the roadblocks to targeting EGFR-driven cancers	45
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	45
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	45
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	45
Understanding the biology of lung cancer brain metastases	44
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	44
CAR T cell therapy: looking back and looking forward	44
Masking T cell engagers mitigates on-target off-tumor activity	44
A new sophistication for breast cancer PDXs	44
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	43
CD8+ T cell killing of MHC class I–deficient tumors	41
Breaking the performance ceiling for neoantigen immunogenicity prediction	41
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	40
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	40
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	40
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	40
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	40
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	40
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	40

Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	39
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	39
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	39
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	39
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	37
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	36
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	36
The meaning of impact	36
Communicating with respect	36
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	35
Leveraging the potential for deintensification in cancer care	35
CD4+ CAR T cells — more than helpers	35
Harnessing the microbiome to restore immunotherapy response	35
Near-infrared optogenetic engineering of bacteria for cancer therapy	34
Radiopharma pipeline builds ahead of key data	34
Artificial intelligence for prostate cancer diagnostics	34
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	34
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	33
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors	33
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	33
Leveraging translational insights toward precision medicine approaches for brain metastases	33
Acute lymphoblastic leukemia displays a distinct highly methylated genome	33
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	32
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	32
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	31
Disparities, aging and childhood cancer	31
Commensal metabolite boosts chemotherapy	31
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	30
The aging lung reawakens dormant tumor cells	30
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	30
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	30
Targeting HIF-1 to treat AML	30
Fibrotic tumors tune metabolism for immune evasion	30
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	29
Stargazing through the lens of AI in clinical oncology	29
Probing clonal dynamics with single-cell genomics	29
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	29
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	29
CAR T cell therapy for multiple myeloma	29
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	29
The landscape of T cell antigens for cancer immunotherapy	29
The growing threat of cyberwarfare in cancer healthcare	29
Remodeling cyclophilin A to target KRAS	29
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	29